<DOC>
	<DOCNO>NCT02456233</DOCNO>
	<brief_summary>This prospective randomized study assess safety efficacy FIRM-guided ablation ( FIRM+PVI ) compare pulmonary vein isolation ( PVI ) without FIRM , treatment symptomatic atrial fibrillation .</brief_summary>
	<brief_title>Evaluation Conventional Ablation With Without Focal Impulse Rotor Modulation Eliminate Human AF</brief_title>
	<detailed_description>Atrial fibrillation ( AF ) affect 2 million Americans . AF may reduce cardiac performance may result thrombus formation leave atrium thromboembolic event , stroke . Ablation eliminate cause arrhythmia increasingly perform since pharmacological therapy suboptimal . Ablation currently target trigger , ablate leave atrial area outside pulmonary vein ( pulmonary vein isolation , PVI ) subject symptomatic AF fail drug . Unfortunately , mixed success best outcomes 50-70 % freedom AF 1 year post ablation . A major issue AF therapy lack knowledge critical region heart cause sustain AF . A recent trial ( STAR-AF2 ) show ablate region empirically - i.e . without define role AF ( line fractionate electrograms ) - improve patient outcome compare PVI alone ( Verma et al , NEJM 2015 ) . However , leave u PVI 50 % success rate trial several trial even paroxysmal AF . We hypothesize guide ablation critical arrhythmia-targeting zone improve success PVI alone . Specifically , hypothesize computational mapping AF find small region call rotor focal source ablate , call Focal Impulse Rotor Modulation ( FIRM ) ablation , show promise eliminate AF substrate . In many single center trial , FIRM improve result PVI alone . This among first randomize comparison FIRM ablation compare PVI alone , address important question field .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Age &gt; 21 year 2 . Reported incidence least two documented episode symptomatic paroxysmal persistent atrial fibrillation ( AF ) 3 month precede trial entry ( least one episode document 12lead ECG ECG rhythm strip ) . Ideally , patient implant continuous ECG recorder place &gt; 30 day prior procedure document AF episodes percentage time AF ( `` burden '' ) prior ablation 3 . Male Women without childbearing potential ( surgically sterile without period 12 month ) , Women childbearing potential pregnant per serum HCG lab test 4 . Refractory least one Class I III antiarrhythmic medication . Drug dose must therapeutic stable 5 . Willingness , ability commitment participate baseline followup evaluation without participation another clinical trial ( unless document approval receive sponsor ) 6 . Oral anticoagulation require subject score two base follow criterion ( CHA2DS2VASc ) congestive heart failure ( 1 point ) hypertension ( 1 point ) age 75 year old ( 2 point ) diabetes ( 1 point ) prior stroke transient ischemic attack ( 2 point ) vascular disease ( include coronary artery disease , CAD ) ( 1 point ) age 65 year old ( 1 point ) gender category : female ( 1 point ) Preprocedural anticoagulation ideally continuous 3 week prior procedure , clinically indicate , INR &gt; 2 patient take warfarin . 7 . Patient willing able remain anticoagulation therapy minimum 3 month post procedure subject , potentially indefinitely post procedure patient CHA2DS2VASc score &gt; or= 2 8 . Signed , informed consent full discussion risk benefit therapy arm , concept randomization 9 . NYHA Class 0 , I II stable medical therapy &gt; 3 month 10 . Left atrial diameter &lt; or= 5.5cm ( CT MRI preprocedure , intracardiac echocardiography , document image large dimension ) 11 . LVEF &gt; or= 40 % 12 . Sustained AF procedure : If patient experience spontaneous sustain AF ( &gt; 10 min ) procedure , typically paroxysmal AF patient , sustain AF induce routine fashion burst pace initially coronary sinus , site , isoproterenol infusion . Using intensive AF induction method ( Narayan , J Cardiovasc EP ; 2012 ; 23 ( 5 ) : 447454 ) sustain AF induce &gt; 90 % paroxysmal AF patient present sinus rhythm . If AF sustain , patient meet inclusion criterion protocol patient undergo AF ablation per physician direction . 1 . Reversible Cause Atrial Fibrillation : Atrial fibrillation reversible cause ( e.g. , surgery , hyperthyroidism , pericarditis ) ; Cardiac thoracic surgery ( e.g. , valve repair coronary artery bypass grafting , CABG ) within last 180 day ; AF secondary electrolyte imbalance , thyroid disease 2 . AntiCoagulation Contraindicated : Contraindication Heparin ; Contraindication Warfarin novel oral anticoagulant ( e.g. , dabigatran , rivaroxabanm apixaban ) ; History significant bleeding abnormality 3 . Clotting Diathesis : History significant blood clot abnormality , systemic thrombus systemic embolization 4 . Cardiac Prosthesis : ASD closure device , LAA closure device , prosthetic mitral tricuspid valve 5 . Thrombus Mass : Atrial clot/thrombus image transesophageal echocardiogram ( TEE ) within 72 hour procedure ; Intramural thrombus cardiac mass may adversely affect catheter introduction manipulation ; Significant pulmonary embolus within 6 month enrollment 6 . Acute illness active systemic infection sepsis may ordinarily warrant postponement procedure 7 . History recent cerebrovascular disease ( stroke TIA ) systemic thromboembolism within &lt; 6 month 8 . Severe Heart Failure : NYHA class III , IV ; Heart failure stable medical therapy ; Pulmonary edema may make planned anesthesia sedation difficult 9 . NonStable Coronary Disease : Stable/unstable angina ongoing myocardial ischemia ; Myocardial infarction ( MI ) within past 3 month 10 . Structural heart disease clinical significance include : Congenital heart disease abnormality correction prohibit increase risk ablation Acquired heart disease may increase risk ablation , significant ventricular septal defect post myocardial infarction Rheumatic valve disease , since produce unique AF phenotype Extreme leave atrial enlargement , define LA volume index &gt; 60 ml/m2 , PVI low success 55 mm basket small atria 11 . Planned Cardiac Surgery : If cardiac transplantation cardiac surgery plan within 12 month follow period trial 12 . Life expectancy le 12 month ( followup period trial ) 13 . Significant pulmonary disease ( e.g. , COPD ) disease significantly increase risk patient sedation anesthesia 14 . Untreatable allergy contrast medium 15 . Electrolyte imbalance : At time ablation procedure , clinically significant abnormality serum potassium , sodium , magnesium electrolyte affect suitability patient ablation time</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>rotor</keyword>
	<keyword>FIRM</keyword>
	<keyword>paroxysmal atrial fibrillation</keyword>
	<keyword>persistent atrial fibrillation</keyword>
	<keyword>atrial tachyarrhythmia</keyword>
	<keyword>ablation</keyword>
	<keyword>contact mapping</keyword>
	<keyword>clinical trial</keyword>
	<keyword>signal processing</keyword>
</DOC>